Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan.
Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Thorac Cancer. 2020 Mar;11(3):693-696. doi: 10.1111/1759-7714.13319. Epub 2020 Feb 5.
Thymic carcinoma is a rare epithelial tumor of the thymus with a poor prognosis, and multimodal approaches are important for its treatment. Recently, a number of studies have indicated that S-1 treatment is effective against thymic carcinoma. S-1 plus cisplatin with concurrent radiotherapy is a commonly used treatment for other malignancies, including non-small cell lung cancer (NSCLC). In addition, its safety has been confirmed, and it has been reported to have a marked effect against thymic carcinoma. Therefore, we conducted a phase II study of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced thymic carcinoma, in which the overall response rate was employed as the primary endpoint. The secondary endpoints were overall survival, progression-free survival, and safety.
胸腺癌是一种罕见的胸腺上皮性肿瘤，预后较差，多模式治疗对其治疗至关重要。最近，许多研究表明 S-1 治疗对胸腺癌有效。S-1 联合顺铂同步放化疗是治疗包括非小细胞肺癌（NSCLC）在内的其他恶性肿瘤的常用方法。此外，其安全性已得到证实，并已报道对胸腺癌有显著疗效。因此，我们进行了一项 S-1 联合顺铂同步胸部放疗治疗局部晚期胸腺癌的 II 期研究，以总缓解率作为主要终点。次要终点为总生存期、无进展生存期和安全性。
